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Abstract
Background A pooled post hoc responder analysis was
performed to assess the clinical benefit of alvimopan, a
peripherally acting mu-opioid receptor (PAM-OR) antag-
onist, for the management of postoperative ileus after
bowel resection.
Methods Adult patients who underwent laparotomy for
bowel resection scheduled for opioid-based intravenous
patient-controlled analgesia received oral alvimopan or
placebo preoperatively and twice daily postoperatively
until hospital discharge or for 7 postoperative days. The
proportion of responders and numbers needed to treat
(NNT) were examined on postoperative days (POD) 3–8
for GI-2 recovery (first bowel movement, toleration of
solid food) and hospital discharge order (DCO) written.
Results Alvimopan significantly increased the proportion
of patients with GI-2 recovery and DCO written by each
POD (P \ 0.001 for all). More patients who received
alvimopan achieved GI-2 recovery on or before POD 5
(alvimopan, 80%; placebo, 66%) and DCO written before
POD 7 (alvimopan, 87%; placebo, 72%), with corre-
sponding NNTs equal to 7.
Conclusions On each POD analyzed, alvimopan signifi-
cantly increased the proportion of patients who achieved
GI-2 recovery and DCO written versus placebo and was
associated with relatively low NNTs. The results of these
analyses provide additional characterization and support
for the overall clinical benefit of alvimopan in patients
undergoing bowel resection.
Introduction
Postoperative ileus (POI) is an important clinical problem
that occurs after major abdominal operations and is char-
acterized by the inability to tolerate solid food, absence of
passage of flatus and stool, pain and abdominal distension,
nausea, vomiting, lack of bowel sounds, and accumulation
of gas and fluids in the bowel [1]. Both endogenous opioids
released in the gastrointestinal (GI) tract in response to
stress and exogenous opioids used for pain management
contribute to the complex etiology of POI [2, 3].
Postoperative ileus is associated with prolonged hospital
length of stay (LOS), readmission, and increased risk for
postoperative morbidity [4–8]. Gastrointestinal recovery is
generally expected within 5 days (early recovery period) of
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bowel resection (BR) [9] and recovery delayed beyond 5
postoperative days (PODs) of BR (late recovery period)
increases patient risk for morbidity and the probability of
extending LOS [4, 5, 10–12]. Based on the placebo arms of
alvimopan trials (mean discharge order [DCO] written =
6.1 days) [13] and Health Care Financing Administration
database of major intestinal resections in 150 U.S. hospitals
(mean LOS = 6.5 days) [14], a LOS of 7 days or more may
be considered prolonged. Furthermore, national LOS sta-
tistics (including data representing more than 340,000 U.S.
discharges in 1,054 U.S. hospitals) for large and small BR
indicate that average LOS after these operations is sub-
stantially higher: 10 to 15 days [15]. Prolonged LOS may
be associated with increased postoperative morbidity, such
as nosocomial infections [16]. In addition to the clinical
burden of POI, according to an analysis of a national
database, hospitalization costs for patients with coded POI
were substantially higher compared with patients without
coded POI [10]. Furthermore, there is only one FDA-
approved pharmacologic agent for the acceleration of GI
recovery after BR.
Alvimopan (Entereg, Adolor Corporation, Exton, PA),
a recently approved peripherally acting mu-opioid receptor
(PAM-OR) antagonist, was designed to mitigate the
peripheral GI-related adverse effects of opioids without
compromising centrally based analgesia [17]. Alvimopan
was well tolerated, accelerated GI recovery, and reduced
the time to hospital DCO written and POI-related mor-
bidity after BR without compromising opioid-based anal-
gesia in phase III efficacy trials [4, 18–22]. Although
important, these components alone do not provide a com-
plete assessment of the clinical benefit of a new therapy for
the management of POI.
Therefore, a responder analysis, which takes individual
responses to treatment into account, was performed to
investigate further the clinically meaningful benefit of
alvimopan for the management of POI after BR. This
analysis investigated GI recovery and hospital DCO written
over time during the early (PODs 3–5) and late (PODs 6–8)
recovery periods in patients who received alvimopan or
placebo in North American phase III efficacy trials
[18–22].
Patients and methods
Adult patients (age C 18 years) undergoing laparotomy for
partial small or large BR with primary anastomosis and
who were scheduled for postoperative pain management
with intravenous opioid-based patient-controlled analgesia
were eligible for enrollment [18–22]. Patients were
excluded from eligibility if they were pregnant, currently
using opioids or received an acute course of opioids
([3 doses) within 1 week of study entry, had a complete
bowel obstruction, were undergoing total colectomy,
colostomy, ileostomy, or coloanal or ileal pouch-anal
anastomosis, or had a history of total colectomy, gastrec-
tomy, gastric bypass, short bowel syndrome, or multiple
previous abdominal operations performed by laparotomy.
All patients signed a written, informed consent that was
approved by individual institutional review boards [18–22].
Study design and treatments
This was a pooled post hoc analysis of four randomized,
double-blind, placebo-controlled, phase III trials (14CL302,
14CL308, 14CL313, and 14CL314) [18–22]. The majority
([90%) of patients analyzed received placebo or alvimopan
12 mg at least 30 minutes but no longer than 5 hours before
surgery and then twice daily after surgery until hospital
discharge or for a maximum of 7 PODs (15 doses) while
hospitalized. A multimodal, standardized accelerated post-
operative care pathway was implemented in each study to
facilitate GI recovery consistent with best-care practices: if
the nasogastric tube (NGT) was kept in place after surgery, it
was removed no later than noon on POD 1 before the first
postoperative dose of study medication was administered; a
liquid diet was offered and ambulation was encouraged on
POD 1; solid food was offered on POD 2 [14].
Assessments
Gastrointestinal recovery was assessed by a composite
measurement (GI-2), which included recovery of upper
(toleration of solid food) and lower (first bowel movement)
GI function, with time to achieve GI-2 based on the last
event to occur. Postoperative LOS was defined as the cal-
endar day of surgery to the calendar day of DCO written.
Responder analyses were performed at six cutoff time
points on PODs 3 through 8. Postsurgery days (PSDs) were
defined as 24-hour intervals after the end of surgery time
(last suture or staple). Patients were considered responders
if they achieved GI-2 recovery or DCO written by the
cutoff time point and did not experience subsequent com-
plications of POI. Complications of POI included pro-
longed LOS or readmission within 7 days after initial
hospital discharge attributable to POI, paralytic ileus, or
small intestinal obstruction reported as serious adverse
events. Number needed-to-treat (NNT) analyses were per-
formed to provide an estimate of the number of patients
who would need to be treated to attain a favorable out-
come. This type of analysis is directly applicable to clinical
practice because it demonstrates the effort required to
achieve a particular therapeutic target (e.g., achieving GI
recovery within 5 days or discharge from the hospital less
than 1 week from surgery) [22, 23] and is calculated from
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the absolute difference in the proportion of patients in
alvimopan- and placebo-treated groups achieving an event.
Statistical methods
Fisher’s exact test was used to evaluate the treatment effect
on the proportion of responders at each cutoff time point.
All statistical analyses were performed using SAS version
9.1 or higher (SAS Institute, Cary, NC).
Results
Patients
Of the 2,281 patients randomized in the 4 phase III trials,
1,409 patients underwent BR, received placebo or alvim-
opan, and were included in the modified intent-to-treat
population (Table 1) [4]. Approximately half of all patients
were women (51%), and the mean age was 61 years. The
most common reason for surgery was colon or rectal cancer
(51%).
Assessments
Overall, alvimopan significantly increased the proportion of
patients who achieved GI-2 recovery on each day of the early
and late recovery periods (P\0.001 for all; Fig. 1a). Eighty
percent of patients in the alvimopan group compared with
66% of patients in the placebo group achieved GI-2 recovery
on or before POD 5. Moreover, alvimopan significantly
increased the proportion of patients who achieved GI-2
recovery on each day of the early and late recovery periods
irrespective of age or sex (P B 0.03 for all). Significant
increases (P\0.001 for all) in the proportion of patients who
achieved GI-2 recovery on each day were observed in white
patients; however, significant increases (P\0.05) were not
observed in non-white patients on PSD 3 and 5. Only seven
patients would need to be treated with alvimopan to reduce
the risk associated with longer GI recovery (GI-2 recovery[
5 PSD) for one patient (Fig. 1b).
Alvimopan also significantly increased the proportion of
patients who received DCO written on each day of the
early and late recovery periods (P B 0.001 for all; Fig. 2a).
Consistent with GI-2 recovery results, more patients in the
alvimopan group (87%) received DCO written before POD
7 compared with patients in the placebo group (72%).
Alvimopan significantly increased the proportion of
patients who received DCO written on each day of the
early and late recovery periods regardless of age (P B
0.025 for all). Significant increases (P\0.001 for all) were
observed regardless of sex on each day except for PSD 3 in
women. Significant increases (P \ 0.001 for all) in the
proportion of patients who received DCO written on each
day were observed in white patients. Significant increases
(P \ 0.05) were observed for non-white patients on each
day except PSD 3. The proportion of patients who
remained in the hospital on or after PSD 7 was reduced
from 34% in the placebo group to 19% in the alvimopan
group (P \ 0.001; NNT = 7). Similarly, the proportion of
elderly patients (C65 years old) who received DCO written
on or after PSD 7 was reduced from 35% in the placebo
group to 17% in the alvimopan group (NNT = 5). Overall,
NNT analysis indicated that seven patients would need to
receive alvimopan to reduce the risk associated with
Table 1 Patient demographics and baseline surgery characteristics
(modified intent-to-treat population)a
Placebo
(n = 695)
Alvimopan
(n = 714)
Age (years)
Mean ± SD 60.4 ± 14.1 60.7 ± 14.6
Patients C65 291 (41.9) 308 (43.1)
Race
White 589 (84.7) 599 (83.9)
Black 67 (9.6) 77 (10.8)
Hispanic 28 (4.0) 29 (4.1)
Asian 8 (1.2) 7 (1.0)
Native American 1 (0.1) 1 (0.1)
Other 2 (0.3) 1 (0.1)
Sex
Female 362 (52.1) 358 (50.1)
BMI
Mean ± SD (kg/m2) 28.5 ± 6.2 27.7 ± 6
Patients with BMI C 30 kg/m2 231 (33.2) 203 (28.4)
Primary reason for surgery
Colon or rectal cancer 349 (50.2) 374 (52.4)
Diverticular disease 114 (16.4) 109 (15.3)
Takedown 62 (8.9) 73 (10.2)
Intestinal polyps 65 (9.4) 56 (7.8)
Crohn’s disease 35 (5.0) 49 (6.9)
Other 70 (10.1) 53 (7.4)
Surgery type
Small BR 50 (7.2) 65 (9.1)
Large BR 645 (92.8) 649 (90.9)
Surgery duration (h)
Overall mean ± SD 2.2 ± 1.1 2.1 ± 1.1
There were no significant differences in patient demographics or
baseline characteristics between treatment groups. Data are numbers
with percentages in parentheses unless otherwise indicated. Adapted
with permission from Elsevier: Wolff BG, Weese JL, Ludwig KA
et al (2007) Postoperative ileus-related morbidity profile in patients
treated with alvimopan after bowel resection. J Am Coll Surg
204:609–616
SD standard deviation; BMI body mass index; BR bowel resection
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prolonged LOS (DCO written C 7 PSD) for one patient
(Fig. 2b). Postoperative LOS was 1 day shorter in the
alvimopan group (5.6 days) compared with the placebo
group (6.6 days; P \ 0.001).
The rates of readmission for any cause within 10 days
(placebo group, 8%; alvimopan group, 5%; P = 0.01; NNT
= 33) and readmission resulting from complications of POI
within 7 days (placebo group, 2%; alvimopan group, 1%; P
= 0.126; NNT = 100) were low in both groups. Of those
patients who recovered GI-2 function in the early recovery
period (placebo group, n = 461; alvimopan group, n = 572),
7% of patients in the placebo group and 4% of patients in
the alvimopan group were readmitted to the hospital for
any cause (P = 0.043), and no patient in either group was
readmitted for POI, paralytic ileus, or small bowel
obstruction. Furthermore, 12% of patients in the placebo
group (n = 234) and 10% of patients in the alvimopan
group (n = 142) who recovered GI-2 function in the late
recovery period were readmitted for any cause (P = 0.614),
and 6% of patients in the placebo group and 5% of patients
in the alvimopan group were readmitted for POI, paralytic
ileus, or small bowel obstruction (P = 0.818).
Discussion
Although there are no validated patient-reported outcome
measures for POI, there is general agreement that providing
a reduction in the time to GI recovery after BR is clinically
meaningful to the patient. In addition to clinical benefit, it
was previously reported that hospitalization costs for
patients with an International Classification of Diseases,
ninth revision (ICD-9), coded POI were substantially
higher than for patients without coded POI ($18,877 vs.
$9,460) and resulted in longer hospital LOS (11.5 vs.
5.5 days) [10]. The projected annual costs attributed to
managing coded POI is $1.46 billion; however, this was
estimated based on discharge coding of POI and likely
underestimates the true prevalence rate [10]. Thus, in
addition to the clinical burden associated with POI, a
substantial economic burden is apparent.
Previously reported primary efficacy and morbidity
analyses of alvimopan trials have demonstrated that alv-
imopan can significantly accelerate GI recovery in con-
junction with a standardized accelerated postoperative care
pathway without compromising opioid-based analgesia or
Fig. 1 Proportion of patients achieving GI-2 recovery by calendar
day (a) and the number needed to treat to prevent delayed GI-2
recovery by postsurgery day (b) (modified intent-to-treat population).
GI-2 time to first toleration of solid food and first bowel movement
Fig. 2 Proportion of patients receiving discharge order written by
calendar day (a) and the number needed to treat to prevent delayed
discharge order written by postsurgery day (b) (modified intent-to-
treat population)
2188 World J Surg (2010) 34:2185–2190
123
increasing POI-related morbidity and was generally well
tolerated [4, 13, 18–22]. Patients in the alvimopan-treated
groups recovered both upper and lower GI function earlier
compared with patients in the placebo-treated groups [13,
18–22].
The current responder analysis confirmed that alvimo-
pan significantly increased the proportion of patients who
achieved GI-2 recovery during both the early and late
recovery periods in patients who underwent BR via lapa-
rotomy. Alvimopan also significantly increased the pro-
portion of patients who received DCO written during both
the early and late recovery periods. In general, GI-2 and
DCO written were accelerated with alvimopan use
regardless of age or sex; results for race were inconsistent,
most likely because of the smaller sample size for non-
white patients (n = 221) compared with white patients (n =
1,188). Patients treated with alvimopan were discharged
from the hospital 1 day earlier than patients who received
placebo, and rates of readmission were lower in the alv-
imopan group compared with the placebo group. Moreover,
NNT analysis revealed that only a small number of patients
(NNT = 7) would need to be treated to achieve risk
reduction for one patient experiencing delayed GI recovery
or prolonged LOS. In addition, the numbers needed to treat
to reduce the risk of prolonged LOS in elderly patients was
further reduced (NNT = 5). Hence, alvimopan use was
associated with shifting more patients into the earlier phase
of the recovery process. Moreover, NNT calculations
indicated that 33 patients would need to be treated to
prevent one readmission for any cause. A limitation of this
NNT analysis is that by grouping patients together, it is
assumed that patients who achieved or did not achieve GI-2
recovery on each day had an equal level of response, which
is not the case. Thus, this analysis may underestimate the
benefit of alvimopan.
By comparison, preventive therapies, such as the use of
prophylactic antibiotic regimens to prevent postoperative
wound infections in patients undergoing colorectal surgery
or use of low molecular weight heparin or graduated
compression stockings to prevent deep vein thrombosis,
have NNTs ranging from 4 to 17 (calculated using absolute
risk reduction) and have been incorporated into standard
clinical practice based on benefits demonstrated in clinical
trials [23–26] Indeed, wound infection after colorectal
surgery was associated with an increase of approximately
12 hospital days and $1,500–$8,400 in costs, highlighting
the value of instituting preventive therapies such as pro-
phylactic antibiotic use into clinical practice [25]. By
comparison, POI after colorectal surgery was associated
with an increase of 4.9 hospital days and $8,296 in costs
[27]. The NNTs for prevention therapies, such as
prophylactic antibiotic use before colorectal surgery, pro-
vide support that a therapy (e.g., alvimopan) for an acute
postoperative condition (e.g., POI) with similar NNTs
(without increased risk) may represent meaningful patient
benefit if incorporated into standard clinical practice, par-
ticularly because POI is recognized as the most common
cause for increased LOS in these patients, and increased
LOS after major surgery often is associated with increased
risk for nosocomial complications [11, 28]. Additionally,
the overall rate of POI is generally underreported and/or
underrecognized, suggesting that the overall burden of POI
on the health care system may be substantially underesti-
mated [27].
Elderly patients (older than aged 60 years) are at a
higher risk for postoperative morbidity and prolonged LOS
after colorectal surgeries compared with younger patients
[14, 29–32]. In this responder analysis, alvimopan signifi-
cantly increased the proportion of patients who received
DCO written during the early and late recovery periods and
significantly reduced the proportion of patients with pro-
longed hospital stays (DCO written after 7 PODs) in both
the overall and elderly trial populations compared with
placebo. Therefore, these data indicate that alvimopan may
be beneficial to patients who are at greater risk for pro-
longed LOS, such as the elderly. Such reductions in hos-
pital LOS, prolonged LOS, and complications of POI (e.g.,
NGT insertion) may provide a benefit to patients and the
healthcare system [5, 6].
In phase III trials, the accelerated GI recovery observed
in patients who received alvimopan was not associated
with additional complications of POI [4, 18–22]. Postop-
erative ileus-related morbidities, such as postoperative
NGT insertion and prolonged LOS, were lower in patients
who received alvimopan compared with placebo [4]. Fur-
thermore, alvimopan was well tolerated in all phase III
trials [18–22]. In a recent pooled analysis of patients who
underwent BR in three phase III efficacy trials, the most
common treatment-emergent adverse events were nausea
and vomiting, and the incidences of these were lower in the
alvimopan group compared with the placebo group (P \
0.05) [13].
Collectively, the data from this responder analysis in
conjunction with previously reported efficacy, morbidity,
and safety data provide a more complete assessment of the
clinical benefit of alvimopan for the management of POI in
patients who undergo BR. Alvimopan, therefore, may
provide earlier GI recovery and discharge from the hospital
without increased morbidity or interference with opioid
pain management to a greater proportion of patients than
what may be provided by a standardized accelerated
postoperative care pathway alone.
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